Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for CRS Prophylaxis in Haplo-HSCT
NCT03533101Phase 2Completed
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- May 2018
- Primary completion
- May 2019
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in cytokine release syndrome (CRS), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Started May 2018; status: completed.
02
Drugs
tocilizumab
03
Conditions
cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT03533101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03533101.